Skip to Main Content

Paper Details

A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk.
Sci Transl Med
30
2022
27-protein, anthracycline, cancer, cardiovascular disease, diabetes, exenatide, heart failure, myocardial infarction, participants, patient, plasma samples, rheumatoid arthritis, stroke
Author NameAffiliation
Josef CoreshJohns Hopkins University
Christie M BallantyneBaylor College of Medicine
Christie M BallantyneBaylor College of Medicine
Christian MuellerCardiovascular Research Institute, University of Basel
Svati H Shahand Duke Molecular Physiology Institute, Duke University
Svati H Shahand Duke Molecular Physiology Institute, Duke University
Naveed SattarInstitute of Cardiovascular and Medical Sciences, University of Glasgow
Chirag R ParikhJohns Hopkins University
  • 1 - 8

Datasets

Release 1.2